Plus therapeutics to present data from respect-gbm™ clinical trial at the european society for medical oncology congress 2022

Austin, texas, aug. 23, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from the phase 1/2a respect-gbm™ dose escalation clinical trial evaluating the company's lead investigational targeted radiotherapeutic, rhenium-186 nanoliposome (186rnl), in recurrent glioblastoma in an oral presentation at the european society for medical oncology (esmo) congress 2022, being held september 9-13, 2022 in paris, france.
pstv Ratings Summary
pstv Quant Ranking